Status:
WITHDRAWN
Adipose Derived SVF for Aero-digestive & Enterocutaneous Fistulae
Lead Sponsor:
Mayo Clinic
Conditions:
Tracheoesopharyngeal Fistula
Bronchoesophageal Fistula
Eligibility:
All Genders
18-90 years
Phase:
PHASE1
Brief Summary
Determine safety and feasibility of using institutionally prepared autologous, uncultured SVF on patients with aerodigestive and enterocutaneous fistulae secondary to malignancy, trauma or surgery.
Detailed Description
The primary aim of this pilot study is to evaluate the feasibility, time, cost, safety, limitations, and efficacy of the use of institutionally processed SVF for management and closure of aero-digesti...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adults ≥ 18 years old
- Adults ≤ 90 years old
- Fistula or sinus tract opening size between 2 mm and 15 mm in diameter (as measured by comparing its size with the open mouth of a biopsy forceps)
- Inpatient or outpatient setting
- Recurrent or de novo fistulas or sinus tracts
- A prior diagnosis of ADF OR ECF in which the standard therapy has failed or is not applicable
- Fistula or sinus tract location may include:
- Tracheopharyngeal
- Tracheoesophageal
- Bronchoesophageal
- Gastric, duodenal, jejunal, ileal, colonic or anastomotic -communicating to the skin (cutaneous)
- Esophogealgastric anastomosis
- Mediastinal anastomotic leak
- Fistula etiology may include:
- Secondary to previous malignancy with complete remission
- Secondary to radiotherapy as long as complete remission for 5 years has been achieved and documented
- Congenital with or without previous treatment
- Secondary to surgical interventions or endoscopic therapies such as dilation and esophageal manipulation
- Post prolonged tracheal intubation
- Secondary to inflammatory bowel disease
- Secondary to foreign body ingestion
- Secondary to thoracic trauma/crush injuries
- Secondary to caustic ingestion
- Secondary to pneumonectomy or mechanical ventilation
- Esophagomalacia
- The ability of subjects to give appropriate consent or have an appropriate representative available to do so
- The ability of subjects to return for follow up endoscopic assessment as established.
- Exclusion Criteria
- Exposure to any investigational drug or procedure within 3 months prior to study entry.
- Patients with allergy to fibrin glue (TISSEEL) or anesthetics
- Patients with active/ongoing malignancy such as esophageal, lung, tracheal, thyroid, oropharyngeal or gastric cancer
- Patients on active regimen of chemotherapy
- Patients receiving radiation
- Diabetics with poor glucose metabolic control exhibited by an HbA1c \> 9
- If there is evidence, in endoscopy, of dysplastic-appearing mucosa such as Barrett's dysplasia near the fistula or sinus tracts, this will be excluded. Patients that require surgical intervention at the fistula or sinus tract area for any reason
- BMI of \<16 (may difficult lipoaspiration procedure)
- Women who are pregnant or nursing or women of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
- Clinical signs of respiratory tract or pleuro-pulmonary infections
- Prolonged (\> 6 months) use of steroids
- Patients with fistulae or sinus tracts \>15mm
- Drug or alcohol dependence
- Active infectious disease positive for HIV, HTLV, HBV, HCV, CMV (IgM \> IgG) and/or syphilis
- End of life
Exclusion
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2028
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03792360
Start Date
February 1 2021
End Date
February 1 2028
Last Update
April 6 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.